| Medical Condition | Non-segmental vitiligo |
| Facility/Clinic | Accellacare – 8115 Market St Suite 211 |
| Age | 18 years and older |
| Gender | Male & Female |
| Description | A Phase 3 study investigating the efficacy, safety, and tolerability of ritlecitnib in participants with non-segmental vitiligo. |
| Enrollment | Open |
| Patient Commitment Duration | 52 weeks |
| Number of visits in study | 11 |
| Patient Compensation | $101 per study visit |
The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.